EMA Authorised: Exdensur (depemokimab) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA authorised Exdensur (depemokimab) for treatment indications in asthma and nasal polyps. Decision date 12 February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Nasal Polyps

Drugs mentioned

• EXDENSUR (DEPEMOKIMAB)

Snippet

Status: Authorised. Therapeutic area: Asthma;Nasal Polyps. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 12/02/2026